62–64 A retrospective analysis of PHEN used concurrently with TPM, either separately or in fixed-dose combination showed a trend for a lower rate of major adverse cardiovascular events (MACE) and other cardiovascular outcomes among those receiving PHEN/TPM (including the fixed-dose combination) than among the unexposed cohort (HR: 0.24; 95% CI, 0.03 to 1.70 for fixed-dose PHEN-TPM). 90 However, the cardiovascular safety of t
1
—
—